NCT05662215View on ClinicalTrials.gov

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

December 6, 2022

Primary Completion Date

August 8, 2023

Study Completion Date

August 8, 2023

Conditions
Healthy Participants
Interventions
DRUG

CK-3828136

CK-3828136

DRUG

Placebo for CK-3828136

Placebo for CK-3828136

Trial Locations (1)

75247

Labcorp Clinical Research Unit Inc., Dallas

Sponsors

Lead Sponsor

Cytokinetics
All Listed Sponsors
lead

Cytokinetics

INDUSTRY

NCT05662215 - A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter